University of Virginia (UVA) Cancer Center to Use Theraclion's HD Technology
21 Dezember 2022 - 6:00PM
Business Wire
Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE)
(Paris:ALTHE), an innovative company developing a robotic
platform for non-invasive ultrasound therapy, announces that it
has signed a commercial partnership with the University of Virginia
(UVA), in the United States, for the use of Theraclion's latest
technology in a new experimental breast cancer treatment. This
pilot study, which has received FDA (Food & Drug
Administration) approval, will evaluate the combined effect of high
intensity focused ultrasound (HIFU) and low dose chemotherapy on
the immune response to breast cancer. The aim is to add HIFU into
routine breast cancer treatment.
Theraclion's valuable technology in breast cancer
treatment
The HD technology has shown excellent clinical results in vein
treatment. Its visualization capabilities and its very high control
of acoustic energy deposition open up new prospects in the use of
High Intensity Focused Ultrasound (HIFU) in breast cancer
treatment.
Building on a successful initial partnership in advanced breast
cancer patients, the University of Virginia (UVA) Cancer Center has
purchased Theraclion's latest HD technology to launch a pilot study
for early breast cancer.
This protocol will evaluate the combined effect of Theraclion's
focused ultrasound and low-dose chemotherapy in patients with early
breast cancer. The 48-patient randomised trial will assess 3 arms:
HIFU combined with chemotherapy, chemotherapy on its own and HIFU
on its own.
If the combination of HIFU and chemotherapy decreases
myeloid-derived suppressor cells and thus increases the patient's
immune response, this combination treatment could offer early
breast cancer patients a better chance of survival.
Prof. David Brenin, Chief of the Division of Breast and Melanoma
Surgical Services at UVA Health, stated that: “By causing acute
thermal cell damage that triggers a local immune response, we
hypothesize that HIFU, in combination with chemotherapy, could
decrease the circulation of cancer cells and increase the activity
of suppressor cells. HIFU could then be used prior to surgery,
potentiating the effect of chemotherapy with the goal of preventing
the expansion of the cancer and its recurrence.”
About Theraclion
At Theraclion we believe that surgery, as we know it, is
outdated. It converts optimistic patients into anxious individuals,
brilliant doctors into exhausted system executors and stretches
healthcare systems to the limit. We have disrupted this convention
by creating extracorporeal treatment platforms. We replace surgery
with a robotic treatment from outside the body using High Intensity
Focused Ultrasound (HIFU). Our leading edge echotherapy platforms
are currently CE marked in non-invasive treatment of varicose veins
with SONOVEIN® and of breast fibroadenomas and thyroid nodules with
Echopulse®.
Located in Malakoff, near Paris, our employees live and breathe
innovation by extensive clinical research and harness artificial
intelligence. The market of varicose veins treatment alone requires
around 5 million procedures annually. It is a dynamic market in
which we change paradigms by making non-invasive echotherapy the
new standard.
For more information, please visit
www.theraclion.com and our patient website
www.echotherapy.com.
Theraclion is listed on Euronext Growth Paris Eligible for the
PEA-PME scheme Mnemonic: ALTHE - ISIN code: FR0010120402 LEI:
9695007X7HA7A1GCYD29
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221221005335/en/
Theraclion contact David AUREGAN Chief Operating Officer
david.auregan@theraclion.com
Theraclion (EU:ALTHE)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Theraclion (EU:ALTHE)
Historical Stock Chart
Von Apr 2023 bis Apr 2024